Summary
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
History
Aptinyx was edstablished in 2015 and isthe first spin-out from the laboratory of Jim O’Shea, MD. The company has developed a novel synthetic small molecule NMDA receptor modulator, which is currently in multiple clinical trials as a potential therapy for a variety of neurological disorders.
Mission
Our mission is to develop innovative and safe therapies that improve the lives of patients suffering from neurological and cognitive disorders. We focus on developing treatments with strong therapeutic potential and improved safety profiles, making them safe and effective therapies for our patients.
Vision
We envision a world where people with neurological and cognitive difficulties have therapies that provide hope and a better quality of life.
Key Team
Mr. Patrick Flavin (Sr. Mang. of Corp. Devel. & Investor Relations)
Ms. Molly Dir (VP of HR)
Dr. Harald Murck M.D., Ph.D. (VP of Clinical & Medical Affairs)
Dr. Kathryn King Ph.D. (Sr. VP of Clinical & CMC Operations)
Mr. Tim Noffke (VP of Program Management & Chief of Staff)
Recognition and Awards
Aptinyx has won a number of awards, such as the 2020 Drug Development Innovation Awards, and have received numerous grants from organizations such as the National Institutes of Health, the Alzheimer's Association and the US Department of Defense.
References
